Archive for March, 2010
« Previous EntriesStarting Metformin Within Three Months Of Diabetes Diagnosis May Increase Drug’s Efficacy.
Tuesday, March 23rd, 2010Medscape (3/22, Larson) reported that, according to a study published in the March issue of the journal Diabetes Care, “starting patients with metformin within 3 months of their diabetes diagnosis increases the drug’s efficacy.” After studying “the electronic records of 1,799 patients with type 2 diabetes who received metformin as their first antihyperglycemic medication,” researchers […]
Higher Lipitor Dose May Lower Heart Attack, Stroke Risk For Some Patients.
Sunday, March 21st, 2010The AP (3/16) reports, “A reanalysis of research data found a high dose of popular cholesterol pill Lipitor [atorvastatin calcium] lowers risk of heart attack and stroke in some patients with both heart disease and kidney disease, the drug’s maker said Monday.” Pfizer Inc. “said the new analysis, which it funded, included patients with both […]
Rosuvastatin cuts LDL-C in children with familial hypercholesterolemia
Sunday, March 21st, 2010Rosuvastatin therapy significantly reduces levels of low-density lipoprotein (LDL) cholesterol and is well-tolerated in adolescents with familial hypercholesterolemia, a randomized placebo-controlled trial has found.
Yet just 40% of children reached the recently recommended LDL cholesterol goal of less than 110 mg/dl (2.84 mmol/l), a finding that the researchers say reflects the patients’ high baseline levels.
The study, […]
Lipid levels affect cognitive function more in early than late old age
Wednesday, March 17th, 2010Source: MedWire News
High lipid levels are a greater risk factor for cognitive dysfunction before the age of 65 years than afterwards, report researchers.
“Cognitive health in old age may be related to cardiovascular risk factors such as serum lipid levels, but how lipids relate to cognitive change is unclear,” say Chandra Reynolds (University of California at […]
Formoterol effective for asthma exacerbations
Monday, March 15th, 2010Results from a systematic review and meta-analysis indicate that the long-acting beta-2 agonist (LABA) formoterol is as effective for the treatment of asthma exacerbations as short-acting beta-2 agonists (SABAs).
“The treatment of acute asthma includes the repetitive administration of SABAs, often in combination with inhaled anticholinergic agents, systemic corticosteroids, and supplemental oxygen,” say Gustavo Rodrigo (Hospital […]
